The present study aimed to address the cost-effectiveness of BRCA-associated treatment (adjuvant olaparib and RRO) secondary to gBRCA testing in TNBC and all HER2-negative BC (inclusive of TNBC) patients under different scenarios in China and the USA. Here, ERBB2 is linked to breast cancer.